The AMR Action Fund is the world's largest public-private partnership dedicated to combating antimicrobial resistance (AMR). It invests in biotech companies developing new antibiotics, antifungals, and other antimicrobials, aiming to bring 2-4 new treatments to market by 2030[1][2]. The fund provides capital and strategic support to address unmet medical needs for priority pathogens[4]. Its target audience includes biotech companies and global health stakeholders. The unique selling proposition is its collaborative approach to bridge the funding gap in antibiotic R&D and advocate for market reforms to sustain innovation in this critical field[5].